About Us

New classes of antibiotics are urgently needed

Between 1930 and 1962 there were more than 20 novel classes of antibiotics discovered. Since then only two new classes have been marketed. Analogue development of existing classes has been the mainstay for the last several decades, and this strategy has proven to be reasonably effective until recently. The emergence of widespread resistance has rendered entire classes of antibiotics ineffective and physicians are now left with little to no treatment options. Hence, novel classes of antibiotics are urgently needed as a way forward to treat antibiotic-resistant bacteria that are rapidly spreading across the globe.

Why we started Forge Therapeutics

Forge Therapeutics was started to discover and develop novel classes of antibiotics. We are employing our proprietary chemistry technology to discover novel small molecule inhibitors of bacterial metalloenzymes. The scientists at Forge have identified novel lead compounds ready for advancing through lead optimization activities toward clinical studies. Working with our partners at Evotec, CARB-X, NIH/NIAID, Basilea, and Roche we will accelerate these activities in a highly scientific manner aiming to develop novel classes of antibiotics that address several of the bacteria on the CDC urgent threat list including carbapenem-resistant Enterobacteriaceae, multidrug-resistant Acinetobacter, and multidrug-resistant Pseudomonas.